Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: An observational study

Journal of Rheumatology

Volumn 43, Issue 12, 2016, Pages 2149-2154

  Costa, Luisa ^a   Caso, Francesco ^a   Del Puente, Antonio ^a   Di Minno, Matteo Nicola Dario ^a   Peluso, Rosario ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Dmard; Malignancies traditional; Psoriatic arthritis; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGE; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER INCIDENCE; CARCINOID; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DISEASE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGIOMA; METABOLIC SYNDROME X; NONHODGKIN LYMPHOMA; OBESITY; OBSERVATIONAL STUDY; OVARY CANCER; OVARY TERATOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PSORIATIC ARTHRITIS; SEMINOMA; SKIN CARCINOMA; THYROID CARCINOMA; THYROID DISEASE; THYROID PAPILLARY CARCINOMA; TONGUE CARCINOMA; UTERUS CANCER; AGED; ANTAGONISTS AND INHIBITORS; INCIDENCE; MIDDLE AGED; NEOPLASM; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85002537722     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160542     Document Type: Article

References (45)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F, et al. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 2012;89:49-53.
3. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012;31:711-5.
4. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM. Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology 2015;51:2215-23.
5. Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41:1357-65.
6. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210-2.
7. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
8. Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHugh J, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria-a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012;39:154-6.
9. Joshi P, Dhaneshwar SS. An update on disease modifying antirheumatic drugs. Inflamm Allergy Drug Targets 2014;13:249-61.
10. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2:346-57.
11. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013;44:183-93.
12. Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 2014;58:61-9.
13. Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 2013;80:165-70.
14. Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol 2015;34:1571-80.
15. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, et al; Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011;29:S28-41.
16. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
17. Armstrong AW, Coates LC, Espinoza LR, Ogdie AR, Rich P, Soriano ER. Infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1438-41.
18. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
19. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008;58:82-7.
20. Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, et al; SABER Collaboration. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58.
21. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237-42.
22. Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7.
23. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-83.
24. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9.
25. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006;142:1132-5.
26. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26 Suppl 3:22-31.
27. Stern RS, Bagheri S, Nichols K. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002;47:33-9.
28. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042-5.
29. van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol 2015; 29:752-60.
30. Nannini C, Cantini F, Niccoli L, Cassarà E, Salvarani C, Olivieri I, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 2009;61:801-12.
31. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64:1035-50.
32. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010; 49:697-705.
33. Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 2014;66:1472-81.
34. Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, et al; BIOBADASER Study Group; EMECAR Study Group. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011;41:71-80.
35. Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014;33:833-9.
36. Jókai H, Szakonyi J, Kontár O, Marschalkó M, Szalai K, Kárpáti S, et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol 2013;69:523-9.
37. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705-12.
38. Avgerinou G, Tousoulis D, Siasos G, Oikonomou E, Maniatis K, Papageorgiou N, et al. Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 2011;151:382-3.
39. Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L, et al. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 2014;33:543-7.
40. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014;33:273-6.
41. Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014;2014:862969.
42. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19:7867-73.
43. Temel T, Cansu DÜ, Korkmaz C, Kasifoglu T, Özakyol A. The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections. Int J Rheum Dis 2015;18:40-5.
44. Caso F, Cantarini L, Morisco F, Del Puente A, Ramonda R, Fiocco U, et al. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther 2015;15:641-50.
45. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012;38:497-505.